When a “Stable” MRI Isn’t a Stable Patient Pt II: Genetics, Inflammation, and the Hidden Drivers of Cognitive Decline
In March, we explored a difficult but increasingly common clinical reality: patients whose MRIs appear “stable” while their cognition continues to decline. In this follow-up TruNeura Mastermind session, clinicians revisited that same patient case with new genomic insights — revealing how genetics, inflammation, mitochondrial dysfunction, and metabolic patterns can radically reshape both risk assessment and treatment strategy.
The discussion centered on a patient with APOE4/4, TREM2, cerebral amyloid angiopathy, microbleeds, anxiety, and progressive cognitive symptoms. On paper, the case appeared high risk. But the deeper genomic analysis told a much more nuanced story.
Looking Beyond APOE4 Alone
One of the biggest themes from the session was the danger of reducing cognitive decline risk to APOE status alone.
While the patient carried two APOE4 alleles, clinicians emphasized that APOE4 is only part of the picture. Additional genes — including TOMM40, BCHE, inflammatory pathways, mitochondrial genes, detox pathways, and estrogen metabolism genes — significantly modify both risk and treatment response.
In this case, the absence of certain high-risk variants dramatically changed the interpretation of the patient’s prognosis.
Rather than treating APOE4 as a fixed outcome, the conversation focused on identifying the mechanisms actively driving dysfunction in this individual patient.
Neuroinflammation as a Major Driver
The patient’s TREM2 variant became a major focus of the discussion.
TREM2 is closely tied to microglial activation — the brain’s immune response system. When overactivated, microglia can remain in a chronic inflammatory state, contributing to neuronal damage and accelerating cognitive decline.
Clinicians discussed how this type of neuroinflammation often requires layered interventions rather than a single therapy approach. The case highlighted the importance of combining targeted nutrition, anti-inflammatory support, mitochondrial therapies, and metabolic interventions simultaneously when patients are already symptomatic.
This represented a broader shift away from generalized cognitive protocols and toward precision brain health strategies rooted in each patient’s unique biology.
The Metabolic Side of Cognitive Decline
Another key insight was the relationship between insulin resistance, mitochondrial dysfunction, and cognition.
Even with relatively normal standard labs, the patient’s genomic profile suggested significant susceptibility to metabolic dysfunction affecting the brain. The ketogenic diet and mitochondrial support strategies became central parts of the treatment conversation, reinforcing the growing understanding that cognitive decline is often deeply tied to energy metabolism.
The session also emphasized how genomics can help clinicians prioritize interventions instead of overwhelming patients with dozens of disconnected recommendations.
Why Genomics Changes Clinical Decision-Making
Throughout the discussion, clinicians repeatedly returned to one core idea: genomics is most valuable when it changes what you do clinically.
Rather than functioning as a standalone data report, genomic analysis was presented as a decision-support tool that helps clinicians identify:
Which pathways matter most for a specific patient
Which interventions are most likely to work
Which risks require aggressive early intervention
Which therapies may be unnecessary or ineffective
The session also explored how AI-assisted genomic interpretation tools are making this process faster and more clinically accessible — allowing practitioners to move from raw genetic data to actionable treatment plans more efficiently than ever before.
Precision Brain Health Requires Precision Context
One of the clearest takeaways from the Mastermind was that cognitive decline rarely comes from a single cause.
Two patients may share the same diagnosis while having completely different drivers underneath the surface: inflammation, vascular dysfunction, detox impairment, mitochondrial decline, hormone signaling, immune activation, or metabolic dysfunction.
That complexity is exactly why TruNeura’s clinician community continues focusing on systems-based, personalized approaches to brain health instead of relying solely on conventional imaging or generalized protocols.
Upcoming Event: IntellxxDNA Annual Conference on Applied Genomics
We’re excited to partner with IntellxxDNA for the upcoming Annual Conference on Applied Genomics, taking place July 24-26 in Austin, Texas.
This conference is designed for clinicians who want to apply genomics in a way that is clinically practical, immediately actionable, and directly relevant to the patients already in their practice.
Sessions will focus on:
Real patient cases and intervention strategies
Cognitive decline, inflammation, and precision medicine
New advances in genomic clinical decision support
Practical implementation workflows for busy practices
Featured sessions include:
Dr. Sharon Hausman-Cohen and Carol Bilich unveiling major new IntellxxDNA platform enhancements
Dr. Kristine Burke presenting cognition-focused genomic case studies
Dr. Aunna Herbst sharing high-impact SNP prioritization strategies across multiple conditions
An optional Thursday evening peptide dinner discussion with Dr. William Seeds is also available for registered attendees.
Early Bird pricing ends May 29.